CANY
TMO icon

Caxton Associates (New York)’s Thermo Fisher Scientific TMO Stock Holding History

Caxton Associates (New York)’s Portfolio TMO Stock Details TMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-4,914
Closed -$2.61M – 583
2023
Q4 		$2.61M Buy
4,914
+2,600
+112% +$1.26M 0.13% 91
2023
Q3 		$1.17M Sell
2,314
-2,727
-54% -$1.45M 0.16% 120
2023
Q2 		$2.63M Buy
5,041
+3,872
+331% +$2.09M 0.39% 41
2023
Q1 		$674K Buy
+1,169
New +$659K 0.1% 214
2022
Q1 		– Sell
-1,042
Closed -$695K – 702
2021
Q4 		$695K Buy
+1,042
New +$651K 0.07% 188
2021
Q3 		– Sell
-2,741
Closed -$1.38M – 599
2021
Q2 		$1.38M Buy
2,741
+1,145
+72% +$540K 0.15% 49
2021
Q1 		$728K Buy
+1,596
New +$762K 0.07% 107
2020
Q4 		– Sell
-2,311
Closed -$1.02M – 312
2020
Q3 		$1.02M Buy
+2,311
New +$955K 0.11% 57
2019
Q3 		– Sell
-1,232
Closed -$362K – 541
2019
Q2 		$362K Buy
1,232
+486
+65% +$134K 0.04% 250
2019
Q1 		$204K Buy
+746
New +$186K 0.03% 336
2018
Q4 		– Sell
-1,003
Closed -$245K – 465
2018
Q3 		$245K Sell
1,003
-4,387
-81% -$1.01M 0.02% 352
2018
Q2 		$1.12M Buy
+5,390
New +$1.14M 0.06% 156
2017
Q4 		– Sell
-3,300
Closed -$624K – 524
2017
Q3 		$624K Hold
3,300
– – 0.02% 263
2017
Q2 		$576K Buy
+3,300
New +$554K 0.02% 282
2017
Q1 		– Sell
-40,000
Closed -$5.64M – 444
2016
Q4 		$5.64M Buy
+40,000
New +$5.9M 0.25% 74
2015
Q2 		– Sell
-30,000
Closed -$4.03M – 201
2015
Q1 		$4.03M Buy
+30,000
New +$3.87M 0.17% 98
2014
Q4 		– Sell
-45,000
Closed -$5.48M – 196
2014
Q3 		$5.48M Buy
+45,000
New +$5.47M 0.18% 92
2014
Q1 		– Sell
-23,683
Closed -$2.64M – 262
2013
Q4 		$2.64M Buy
+23,683
New +$2.35M 0.08% 100

Other funds holding TMO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Caxton Associates (New York)'s TMO Position: Q1 2024 in Review

Caxton Associates (New York) sold out of Thermo Fisher Scientific (TMO) in Q1 2024, closing a stake of 4,914 shares — an estimated $2.61M sold.

Caxton Associates (New York) first reported a position in TMO in Q4 2013 and held it in 18 quarters. The position peaked at $5.64M in Q4 2016. 2,527 funds tracked by Wall St. Rank hold TMO as of Q1 2024.

  • Caxton Associates (New York) reported no remaining Thermo Fisher Scientific position as of Q1 2024 after selling out during the quarter.
  • Caxton Associates (New York) sold 4,914 Thermo Fisher Scientific shares in Q1 2024, an estimated $2.61M.
  • Caxton Associates (New York) first reported a position in Thermo Fisher Scientific in Q4 2013 and held it in 18 quarters.
  • Caxton Associates (New York)'s Thermo Fisher Scientific position peaked at $5.64M in Q4 2016.
  • 2,527 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q1 2024.

Based on Caxton Associates (New York)'s 13F filing for Q1 2024, filed 15 May 2024.